Press releases

Initial six-month results show positive outcomes in diabetic patients; safety events for diabetic subset lower than overall patient population

International data suggests low revascularization rates for both TAXUS stent and PROMUS™ (XIENCE™ V) stent

PROMUS Stent joins market-leading TAXUS® Paclitaxel-Eluting Coronary Stent Systems

Results expected to continue to support safety and performance of Boston Scientific's second-generation drug-eluting stent system

Company also to host WCC symposia on drug-eluting stents, therapies in cardiac rhythm management and carotid artery disease